Noubar Afeyan, Director at Moderna, Inc. (MRNA), sold 30,000 shares at $119.84 ($3.6M) on 2024-07-31, disclosed to the SEC on 2024-08-02.
Scheduled sale ($3.6M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $118.96 | 4,599 | $547K | 15.2% |
| 2 | $118.96 | 4,599 | $547K | 15.2% |
| 3 | $119.84 | 5,664 | $679K | 18.9% |
| 4 | $119.84 | 5,664 | $679K | 18.9% |
| 5 | $120.88 | 3,428 | $414K | 11.5% |
| 6 | $120.88 | 3,428 |
| $414K |
| 11.5% |
| 7 | $121.62 | 1,309 | $159K | 4.4% |
| 8 | $121.62 | 1,309 | $159K | 4.4% |
| Total | $119.96 avg | 30,000 | $3.6M | 100% |
| Filing → |
| MRNA | SELL | 2025-12-15 | $1.4M | — | Filing → |
| MRNA | SELL | 2024-07-26 | $2.9M | — | Filing → |
| MRNA | SELL | 2024-07-19 | $3.0M | — | Filing → |